Terray is a biotechnology company with the technology, data, and mindset to radically change the way we discover and develop small molecule therapeutics. We explore molecules and targets broadly and deeply with a sophisticated integration of ultra-high throughput experimentation, generative AI, biology, medicinal chemistry, automation, and nanotechnology. Everything the company does is grounded in an iterative approach, producing massive amounts of precise, purpose-built data that gets increasingly valuable with each cycle of design and experimentation. The company’s platform uniquely blends experimentation and computation to improve the cost, speed, and success rate of small molecule drug discovery and development.
External link for Terray Therapeutics
129 N Hill Ave
103
Pasadena, California 91106, US
Interested in learning more about Terray and the role of AI in drug discovery? Catch co-founder, Eli Berlin, on the mainstage at synbiobeta on 5/6 in San Jose with Patrick Malone, MD PhD of KdT Ventures, Cynthia Hong, Novartis, and Kim Branson, GSK.
I’m excited to speak at #SynBioBeta2025 where synthetic biology's future takes shape! Join me on May 5–8 in San Jose, CA, to explore innovative breakthroughs, and discuss biotech’s next chapter.
Terray is excited to Support Foothill Unity Center Inc! Please join us! In times of crisis, the strength of a community is measured by how we come together to support one another. The Eaton fire was just a few miles from our Headquarters in Monrovia, California, and most of our team lives in what were mandatory evacuation areas. We are grateful for the firefighters and first responders, and heartbroken for all those impacted by the devastation – including members of our team. Thankfully, our headquarters and operations were not impacted, and as the team has supported each other in amazing ways at Terray, we have also come together to support our community through our work with the Foothill Unity Center, which is just blocks away from our HQ and has been a pillar of care and relief for those in need for years. Their work is especially vital in the aftermath of the recent fires. Terray has been a longtime volunteer and supporting partner of Foothill Unity Center—whether through their back-to-school drive, distribution efforts, or community relief initiatives. Recently we volunteered in their distribution center and are grateful for the opportunity to stretch our growth-stage biotech budget to support their work with a $20,000 donation. A huge thank you to the team at Foothill Unity Center for all they do! For all our amazing partners, collaborators, investors, suppliers, and friends who reached out to ask how they can support those impacted, please consider supporting Foothill Unity as they continue to deliver critical support to those impacted. #Team #Community
Thank you to Elizabeth Eaton for the thoughtful coverage! We are grateful for the opportunity to share our perspectives alongside Ramy Farid and Karen Akinsanya at Schrödinger and longtime investor Patrick Malone, MD PhD at KdT Ventures. #drugdiscovery #biotech #generativeAI #ML
Covering software and technology is certainly not my strong suit as a pharma reporter, but I've been fascinated by the steady stream of companies that have launched over the last few years with AI tech for drug development. Now that AI has become part of our everyday lives thanks to ChatGPT, it seems there's a general expectation that the technology will revolutionize every industry. But journalists are skeptical by nature, so I set out to cut through the hype and the buzzwords to get to the core of AI: How is the technology used for drug development today, what are its real, tangible benefits, and what we might achieve in the future? I sat down with leaders from Schrödinger, Terray Therapeutics and KdT Ventures to have a grounded conversation on why some of the enthusiasm for AI in drug discovery is justified, and where we might need a dose of realism. Read the story here, with insights from Karen Akinsanya, Ramy Farid, Eli Berlin, Feroze U. and Patrick Malone, MD PhD: https://lnkd.in/g6SenJUf
Terray Therapeutics reposted this
I’ll be exploring how laboratory robotics are evolving into real-time data producers at Terray Therapeutics, enabling on-the-fly informatics that transform workflows. This includes bridging the gap between previously unintegrated platforms by developing coding solutions and utilizing API endpoints to seamlessly communicate with modern Laboratory Information Management Systems (LIMS). Looking forward to sharing insights and exchanging ideas with fellow innovators—see you there! #SLAS2025 #TerrayTherapeutics #LaboratoryAutomation #Informatics #LIMSIntegration
Want to make your life easier? Let #Agilent show you the power of automation on Day 3 at #SLAS2025. Jordan Ashlock of Terray Therapeutics is presenting our tutorial session in Room 24B from 2:00 p.m. to 3:00 p.m. Mark your calendars 🗓️ and register here to be a part of it ➡️ https://lnkd.in/eAmxCuqN
Thank you to Amazon Web Services (AWS) and NVIDIA for highlighting Terray Therapeutics at the #comBINDbio roundtable at #JPM2025!
Couldn’t have asked for a better start to #JPM2025 than chairing a panel of distinguished #generativeAI #innovators and #thoughtleaders at our Amazon Web Services (AWS) offices in San Francisco as part of our #comBINDbio roundtable series in partnership with NVIDIA. Aviv Regev, EVP of Research and Early Discovery Genentech, Chris Picardo, Partner Madrona, James Watson, Operating Partner Andreessen Horowitz and Eli Berlin, Co-founder/COO/CFO Terray Therapeutics shared their insights about AI powered #drugdiscovery, pharma-startup #partnerships, emerging #businessmodels and so much more before a room packed with #techbio leaders. Renee Y. Howard Wright Jack Resnick Eric Zimmerman Yin He Guy Spigelman Alex Merwin Ankur Srivastava
We are excited to announce our multi-target research collaboration with Gilead Sciences to discover and develop novel small molecule therapies! Our tNova platform combines high-throughput chemical experimentation and computational analysis with a generative AI-driven drug discovery engine. This iterative approach applies AI-empowered methods to an extensive library of quantitative, purpose-built, structure activity data to find the right molecules to solve complex problems in drug discovery. We are very proud to strategically partner with Gilead and look forward to leveraging our unique blend of experimentation and computation alongside the deep expertise of our collaborators at Gilead to find transformational small molecule therapeutics that bring relief to patients in need. Learn More: https://lnkd.in/gmZ8A3Kx #drugdiscovery #biotech #generativeAI #ML
Thank you to Brittany Trang and STAT for featuring Terray Therapeutics! Our platform uniquely blends experimentation and computation to deliver on the promise of generative AI for small molecule discovery—finding solutions to the toughest therapeutic challenges for patients with high unmet medical need. Read the Article: https://lnkd.in/gNSMZJb4 #generativeAI #ML #drugdiscovery #biotech
Thank you BioSpace for recognizing Terray Therapeutics as one of the Best Places to Work in Life Sciences 2025! We are honored to be recognized for the third year in a row and deeply proud of our culture and brilliant team. We are hiring — come join us on our journey to advance human health by transforming the speed, cost, and success rate of small molecule drug discovery using computation integrated with novel data at scale. Join Us: https://lnkd.in/gQEC55Jn Learn More: https://lnkd.in/eVW6vt-2 #generativeAI #ML #drugdiscovery #biotech
Interested to learn more about how we built the world's largest experimental chemistry dataset (growing by 500M+ measurements a month), and transformed the way experimentation and computation work together to solve the toughest therapeutic challenges? Join our Chief Platform Officer Craig Schulz at the Future Labs, Automation & Technology conference in San Diego on November 12th!
It's been an amazing month at Terray! We had a great time with Nasdaq celebrating our $120M Series B financing, led by Bedford Ridge Capital and NVentures, NVIDIA’s venture capital arm! And we announced our strategic collaboration with Odyssey Therapeutics to jointly discover and develop first-in-class transcription factor therapies! Our platform uniquely blends experimentation and computation to deliver on the promise of generative AI for small molecule discovery—finding solutions to the toughest therapeutic challenges for patients with high unmet medical need. Learn more about our Series B: Press Release: https://lnkd.in/gcRiJUKd Endpoints News Exclusive: https://lnkd.in/gtieiu2P Learn More about our strategic collaboration with Odyssey Therapeutics: https://lnkd.in/gkaVaEUJ #generativeAI #ML #drugdiscovery #biotech